News | April 10, 2026
Zeto gains FDA nod for new outpatient EEG system promising faster brain health testing
The FDA clearance of Zeto New Wave marks the company’s third cleared device, alongside Zeto WR19 and Zeto ONE
The FDA clearance of Zeto New Wave marks the company’s third cleared device, alongside Zeto WR19 and Zeto ONE
Patients with BRCA mutations often face aggressive disease and poor prognosis
The TWYMEEG approval is supported by numerous preclinical and clinical studies, including the Phase 3 TIMES (Trials of IMeglimin for Efficacy and Safety) program managed jointly by both the companies
New Centre of Excellence at Electronic City campus to offer specialised care in epilepsy, cerebrovascular disorders, neurointervention, skull base and spine surgery
CDSCO-cleared BSM-5700 series targets ICU, NICU, ER, OR and digital health integration under ABDM
The device aims to bring precision neuroscience into clinical trials, accelerating drug development
Alto met its enrollment goal with 83 patients across 13 US clinical sites
The expansion includes a larger technical and service team and increased local procurement
Danish National Genome Center partners with Lifebit to deliver nationwide personalised medicine
The single in vitro diagnostic test helps inform therapy decisions according to clinical guidelines to enable precision medicine earlier in the disease journey
Subscribe To Our Newsletter & Stay Updated
